

Restriction Map of pVSV-G Retroviral Vector. Unique restriction sites are in bold.

## Description

pVSV-G expresses the G glycoprotein of the vesicular stomatitis virus (VSV-G) under the control of the CMV immediate-early promoter (1). VSV-G is used in pseudotyping of Moloney Murine Leukenia Virus (MMLV)-based retroviral vectors by mediating viral entry. VSV-G interacts with phospholipid components of the target cell membrane and fosters the fusion of viral and cellular membranes (2). VSV-G does not require a cell surface receptor and can serve as a surrogate viral envelope protein. pVSV-G Vector includes IVS, a synthetic intron known to enhance the stability of the mRNA (3), the Col E1 origin of replication and bacterial ampicillin rsistance (Amp<sup>r)</sup> gene for propagation and antibiotic selection in bacteria.



Clon**tech** 

United States/Canada 800.662.2566 Asia Pacific +1.650.919.7300 Europe +33.(0)1.3904.6880 Japan +81.(0)77.543.6116

Clontech Laboratories, Inc. ATakara Bio Company 1290 Terra Bella Ave. Mountain View, CA 94043 Technical Support (US) E-mail: tech@clontech.com www.clontech.com

## Use

As part of the Retro-X<sup>TM</sup> Universal Retroviral Expression System (Cat. No. 631530), pVSV-G is cotransfected with a retroviral expression vector into the GP2-293 Packaging Cell Line (4) to produce infectious, replication-incompetent retrovirus. The genes encoding the viral *gag* and *pol* proteins are stably integrated into GP2-293. Because the VSV-G envelope protein causes toxicity by fusing cellular membranes, it must be expressed transiently from pVSV-G during packaging (5). Although the resulting virus can infect target cell lines and transmit a gene-of-interest, it cannot replicate because target cell lines lack the viral structural and polymerase/integrase genes. The separate introduction and integration of the viral genes into the packaging cell line and the use of minimal viral sequences in the vector minimize the chance of producing replication-competent virus due to recombination events.

(PR37005; published 24 June 2003)

## **Location of Features**

- CMV promoter: 1-768
- Rabbit β-globin IVS: 768–1432
- VSV-G envelope gene:
  - Start codon: 1450–1452; stop codon: 2983–2985
- β-globin poly A: 3288–3293
- Col E1 origin of replication
  Site of replication initiation: 4087
- Ampicillin resistance gene (β-lactamase): Start codon: 5712–5710; stop codon: 4853–4851

# Propagation in *E. coli*

- Suitable host strains: DH5 $\alpha$ , HB101, and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 µg/ml) to E. coli hosts.
- E. coli replication origin: Col E1
- Copy number: low

### References

- 1. Yee, J. K., et al. (1994) Proc. Natl. Acad. Sci. USA 91:9564–9568.
- 2. Emi, N., et al. (1991) J. Virol. 65:1202–1207.
- 3. Huang, M. T. F. & Gorman, C. M. (1990) Nucleic Acids Res. 18(4):937–947.
- 4. Witte, O. N. & Baltimore, D. (1977) Cell 11:505-511.
- 5. Burns, J. C., et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037.

**Notes:** Due caution must be exercised in the production and handling of recombinant retrovirus. Appropriate NIH, regional, and institutional guidelines apply.

The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

#### Notice to Purchaser

This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes, nor is it intended for human use. Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written approval of Clontech Laboratories, Inc.

Clontech, Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc. Clontech is a Takara Bio Company. ©2005